GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (HAM:SBH) » Definitions » Liabilities-to-Assets

Sangui Biotech International (HAM:SBH) Liabilities-to-Assets : 12.36 (As of Mar. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Sangui Biotech International Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Sangui Biotech International's Total Liabilities for the quarter that ended in Mar. 2023 was €1.03 Mil. Sangui Biotech International's Total Assets for the quarter that ended in Mar. 2023 was €0.08 Mil. Therefore, Sangui Biotech International's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2023 was 12.36.


Sangui Biotech International Liabilities-to-Assets Historical Data

The historical data trend for Sangui Biotech International's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Liabilities-to-Assets Chart

Sangui Biotech International Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.46 8.49 6.84 7.54 7.83

Sangui Biotech International Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.76 7.83 7.81 10.85 12.36

Competitive Comparison of Sangui Biotech International's Liabilities-to-Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangui Biotech International's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's Liabilities-to-Assets falls into.



Sangui Biotech International Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Sangui Biotech International's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2022 is calculated as:

Liabilities-to-Assets (A: Jun. 2022 )=Total Liabilities/Total Assets
=0.971/0.124
=7.83

Sangui Biotech International's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2023 is calculated as

Liabilities-to-Assets (Q: Mar. 2023 )=Total Liabilities/Total Assets
=1.026/0.083
=12.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sangui Biotech International  (HAM:SBH) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Sangui Biotech International Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangui Biotech International (HAM:SBH) Business Description

Traded in Other Exchanges
Address
Bleichenbrucke 9, Hamburg, DEU, 20354
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.